|Bid||4.1500 x 1200|
|Ask||4.9500 x 800|
|Day's Range||4.5800 - 4.8000|
|52 Week Range||3.2500 - 17.4000|
|Beta (3Y Monthly)||0.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.86|
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to know who really controls AC Immune SA (NASDAQ:ACIU), then you'll have to look at the makeup of its share regis...
LAUSANNE, Switzerland, April 01, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
Demonstrated high-affinity binding to human Parkinson’s disease-brain derived alpha-synucleinPotentially first diagnostic for detecting and monitoring Parkinson’s diseaseFurther.
Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSP New data further support 18F-PI-2620’s potential as.
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023 Eli Lilly deal validates MorphomerTM platform Initiation of second Phase 2 trial of Tau antibody.
LAUSANNE, Switzerland, March 04, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.
Study complements ongoing trial in the prodromal to mild population LAUSANNE, Switzerland, Feb. 20, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage.
LAUSANNE, Switzerland, Feb. 07, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
Why Did AC Immune SA Stock Crash on January 30?Share price movementsOn January 30, AC Immune SA (ACIU) issued a press release announcing the discontinuation of Phase 3 trials, CREAD 1 and CREAD 2, by Roche Holdings (RHHBY). The decision was based on
Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
Biogen stock slipped Wednesday after Roche and AC Immune opted to scrap two Alzheimer's treatment studies — leading investors to look for details of Biogen's own experimental drug.
Roche Holding and partner AC Immune SA called a halt to two late-stage clinical trials of their crenezumab drug for early Alzheimer's, the latest in a string of failures to find a treatment for the progressive brain disease. The announcement from Roche and its Swiss-based partner AC Immune came after an interim analysis indicated it was unlikely to be effective, the Swiss drugmaker said on Wednesday. Alzheimer's, a fatal disease which affects memory and language as it progresses, is a compelling target for drugmakers as the numbers affected across the globe swell with an ageing population, but experimental Alzheimer's drugs have had a dismal track record, with more than 100 failures.
Genentech's Alzheimer's-fighting drug failed two late-stage studies, but other Bay Area companies are continuing with different approaches to the memory-stealing disease.
Roche Holding will halt two late-stage clinical trials of its crenezumab drug in early Alzheimer's disease after an interim analysis indicated it was unlikely to hits its primary goal, the Swiss drugmaker said on Wednesday. Roche was working on the product with AC Immune.
AC Immune SA (ACIU) announced today that Roche, the parent company of its collaboration partner, is discontinuing the CREAD 1 and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational anti-beta-amyloid molecule, crenezumab, in people with prodromal to mild sporadic Alzheimer’s disease (AD). The decision came after an interim analysis conducted by the Independent Data Monitoring Committee (IDMC).